SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: WalshPC, & RetikAB, VaughanEDJr, WeinAJ, eds. Campbell's Urology, 8th edn. Philadelphia: W. B. Saunders Co, 2002; 1297330.
  • 2
    AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 53047.
  • 3
    Abrams P, Cardozo L, Fall M et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 16778.
  • 4
    Study Group on the Standardization of Treatment in the Field of Urology. Guidelines for Treatment of Benign Prostatic Hyperplasia Based on EBM. Tokyo: Jiho, 2001.
  • 5
    Hieble JP, Bylund DB, Clarke DE et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 1995; 47: 26770.
  • 6
    Lepor H, Tang R, Kobayashi S et al. Localization of the alpha 1A-adrenoceptor in the human prostate. J Urol 1995; 154: 20969.
  • 7
    Murata S, Taniguchi T, Takahashi M, Okada K, Akiyama K, Muramatsu I. Tissue selectivity of KMD-3213, an alpha(1)-adrenoceptor antagonist, in human prostate and vasculature. J Urol 2000; 164: 57883.
  • 8
    Chen Q, Takahashi S, Zhong S et al. Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor. J Urol 2005; 174: 3704.
  • 9
    Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994; 113: 7238.
  • 10
    Schwinn DA. Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2000; 86(Suppl 2): 1120.
  • 11
    Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol 2002; 19: 397404.
  • 12
    Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H. Tokai Urological Clinical Trial Group. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2005; 96: 5816.
  • 13
    Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 2006; 97: 74751.
  • 14
    Shibata K, Foglar R, Horie K et al. KMD-3213, a novel, potent, α1A-adrenoceptor selective antagonist: characterization using recombinant human α1-adrenoceptors and native tissues. Mol Pharmacol 1995; 48: 2508.
  • 15
    Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213) Yakugaku Zasshi 2006; 126: 20916.
  • 16
    Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006; 98: 101924.
  • 17
    Takao T, Tsujimura A, Kiuchi H et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 2008; 15: 9926.
  • 18
    Ogawa T, Uemura H, Sano F et al. Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia. Hinyokika Kiyo 2008; 54: 75764.
  • 19
    Cockett AT, Aso Y, Denis L et al. The members of the committees. Recommendations of the international consensus committee. In: CockettATK, AsoY, ChatelainC, DenisL, GriffithsK, KhouryS, MurphyG, eds. The 2nd International Consultation of Benign Prostatic Hyperplasia. Paris: Pitie Salapatiere, 1993; 55364.
  • 20
    Homma Y, Yoshida M, Seki N et al. Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 2006; 68: 31823.
  • 21
    Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol 1996; 3: 2616.
  • 22
    Nasu K, Moriyama N, Kawabe K et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996; 119: 797803.
  • 23
    Akiyama K, Hora M, Tatemichi S et al. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 1999; 291: 8191.